Purpose: We performed a cost-effectiveness analysis using the PHI (Prostate Health Index),
4Kscore®, SelectMDx™ and the EPI (ExoDx™ Prostate [IntelliScore]) in men with elevated …

Historically, prostate biopsy was performed because of a prostate-specific antigen (PSA)
level exceeding a specific threshold or suspicious findings on digital rectal examination …

Objective To assess the cost‐effectiveness of a new urinary biomarker‐based risk score
(Select MD x; MD xHealth, Inc., Irvine, CA, USA) to identify patients for transrectal …

Introduction Many new markers are now available as an aid for decisions about prostate
biopsy for men without prostate cancer and/or to improve risk stratification for men with …

Purpose: We developed and validated a Prostate Health Index (Beckman Coulter, Brea,
California) based nomogram to predict prostate cancer at extended prostate biopsy …

Purpose SelectMDx (MDxHealth®) is a panel of urinary biomarkers used in conjunction with
traditional risk factors to individualize risk prediction for clinically significant prostate cancer …

OBJECTIVES To develop a logistic regression‐based model to predict prostate cancer
biopsy at, and compare its performance to the risk calculator developed by the Prostate …

OBJECTIVES: To develop a model capable of predicting prostate biopsy outcomes in a
large screening population, with independent validation in the referral setting. METHODS …

Background Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in
the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically …

Study Type–Diagnosis (exploratory cohort) Level of Evidence 2b What's known on the
subject? and What does the study add? In recent years, several nomograms were …